Drugs / PA5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07702162 | Nov 2025 → Feb 2027 expected | cancer | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07702162 ↗ |
| Known as | Pegylated Arginine Deiminase Dimer | “Pegylated Arginine Deiminase Dimer (PA5) Injection” NCT07702162 ↗ |
| Modality | Protein / enzyme biologic | “Biological: PA5” NCT07702162 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT07702162 ↗ |